Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie-Paule Sablin

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Molecular Oncology|August 5, 2020
Fine-needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next-generation sequencing in cancer patients included in the SHIVA02 trialCélia Dupain, Julien Masliah-Planchon, Céline Gu, et al.
Iscience|March 19, 2026
CMV seropositivity associates with poor clinical outcome in triple negative breast cancerRomain-David Seban, Constance Lamy, Luc Cabel, et al.
Anticancer Research|July 5, 2020
Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC StudyPierre Heudel, Suzette Delaloge, Damien Parent, et al.
BMC Biology|February 20, 2024
Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routineCélia Dupain, Tom Gutman, Elodie Girard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2023
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker ResultsPeter Schmid, Nicholas C Turner, Carlos H Barrios, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2020
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> <sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast CancerLillian M Smyth, Kenji Tamura, Mafalda Oliveira, et al.
ESMO Open|April 12, 2018
Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut CurieClémence Basse, Claire Morel, Marie Alt, et al.
Nature Medicine|January 19, 2021
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trialThomas Bachelot, Thomas Filleron, Ivan Bieche, et al.
Nature Cancer|June 30, 2025
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trialEdith Borcoman, Bastien Cabarrou, Miguel Francisco, et al.
International Journal of Cancer|November 1, 2021
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation studySophie Cousin, Jean-Yves Blay, Irene Braña Garcia, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Molecular Oncology|August 5, 2020
Fine-needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next-generation sequencing in cancer patients included in the SHIVA02 trialCélia Dupain, Julien Masliah-Planchon, Céline Gu, et al.
Iscience|March 19, 2026
CMV seropositivity associates with poor clinical outcome in triple negative breast cancerRomain-David Seban, Constance Lamy, Luc Cabel, et al.
Anticancer Research|July 5, 2020
Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC StudyPierre Heudel, Suzette Delaloge, Damien Parent, et al.
BMC Biology|February 20, 2024
Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routineCélia Dupain, Tom Gutman, Elodie Girard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2023
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker ResultsPeter Schmid, Nicholas C Turner, Carlos H Barrios, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2020
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> <sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast CancerLillian M Smyth, Kenji Tamura, Mafalda Oliveira, et al.
ESMO Open|April 12, 2018
Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut CurieClémence Basse, Claire Morel, Marie Alt, et al.
Nature Medicine|January 19, 2021
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trialThomas Bachelot, Thomas Filleron, Ivan Bieche, et al.
Nature Cancer|June 30, 2025
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trialEdith Borcoman, Bastien Cabarrou, Miguel Francisco, et al.
International Journal of Cancer|November 1, 2021
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation studySophie Cousin, Jean-Yves Blay, Irene Braña Garcia, et al.
Pageof 6